Know more

Our use of cookies

Cookies are a set of data stored on a user’s device when the user browses a web site. The data is in a file containing an ID number, the name of the server which deposited it and, in some cases, an expiry date. We use cookies to record information about your visit, language of preference, and other parameters on the site in order to optimise your next visit and make the site even more useful to you.

To improve your experience, we use cookies to store certain browsing information and provide secure navigation, and to collect statistics with a view to improve the site’s features. For a complete list of the cookies we use, download “Ghostery”, a free plug-in for browsers which can detect, and, in some cases, block cookies.

Ghostery is available here for free: https://www.ghostery.com/fr/products/

You can also visit the CNIL web site for instructions on how to configure your browser to manage cookie storage on your device.

In the case of third-party advertising cookies, you can also visit the following site: http://www.youronlinechoices.com/fr/controler-ses-cookies/, offered by digital advertising professionals within the European Digital Advertising Alliance (EDAA). From the site, you can deny or accept the cookies used by advertising professionals who are members.

It is also possible to block certain third-party cookies directly via publishers:

Cookie type

Means of blocking

Analytical and performance cookies

Realytics
Google Analytics
Spoteffects
Optimizely

Targeted advertising cookies

DoubleClick
Mediarithmics

The following types of cookies may be used on our websites:

Mandatory cookies

Functional cookies

Social media and advertising cookies

These cookies are needed to ensure the proper functioning of the site and cannot be disabled. They help ensure a secure connection and the basic availability of our website.

These cookies allow us to analyse site use in order to measure and optimise performance. They allow us to store your sign-in information and display the different components of our website in a more coherent way.

These cookies are used by advertising agencies such as Google and by social media sites such as LinkedIn and Facebook. Among other things, they allow pages to be shared on social media, the posting of comments, and the publication (on our site or elsewhere) of ads that reflect your centres of interest.

Our EZPublish content management system (CMS) uses CAS and PHP session cookies and the New Relic cookie for monitoring purposes (IP, response times).

These cookies are deleted at the end of the browsing session (when you log off or close your browser window)

Our EZPublish content management system (CMS) uses the XiTi cookie to measure traffic. Our service provider is AT Internet. This company stores data (IPs, date and time of access, length of the visit and pages viewed) for six months.

Our EZPublish content management system (CMS) does not use this type of cookie.

For more information about the cookies we use, contact INRA’s Data Protection Officer by email at cil-dpo@inra.fr or by post at:

INRA
24, chemin de Borde Rouge –Auzeville – CS52627
31326 Castanet Tolosan CEDEX - France

Dernière mise à jour : Mai 2018

Menu Logo Principal

Home

Unité de Virologie et Immunologie Moléculaires

Joaquin Castilla (CIC BioGUNE, Bilbao)

16 December 2010 - INRA Jouy-en-Josas

Joaquin Castilla
© J. Castilla
"In vitro studies for evaluating prion transmission between species"

Dr Joaquin Castilla, Ikerbasque Research Professor, CIC bioGUNE - Proteomics unit (Prion lab). Parque tecnológico de Bizkaia. Derio 48160 (Bizkaia). Spain

Joaquin Castilla began working on Prions in 1998. He played a major role in developing Protein Misfolding Cyclic Amplification (PMCA), a technique comparable to PCR that amplifies prion proteins (PrP).

Summary

One of the characteristics of Prions is their ability to infect some species and not others. This phenomenon is known as the transmission barrier. In general, the transmission barrier is expressed by an incomplete attack rate and long incubation times which become shorter after serial inoculation passages. The absence of natural TSE cases and/or failed experimental transmissions has suggested that some species could be resistant for prion diseases.

Unfortunately, the molecular basis of the transmission barrier phenomenon is currently unknown and we cannot predict the degree of a species barrier simply by comparing the prion proteins from two species. We have conducted a series of experiments using the Protein Misfolding Cyclic Amplification (PMCA) technique that mimics in vitro some of the fundamental steps involved in prion replication in vivo albeit with accelerated kinetics. We have used this method to efficiently replicate a variety of prion strains from, among others, mice, hamsters, bank voles, deer, cattle, sheep and humans. The in vitro generated PrPres possess key prion features, i.e. they are infectious in vivo and maintain their strain specificity. We are using the PMCA to generate infectious PrPres from species hitherto considered to be resistant to prion disease and assay the role that certain amino acids play in the transmission barriers.

The correlation between in vivo data and our in vitro results suggest that PMCA is a valuable tool for studying the strength of the transmission barriers between diverse species and for evaluating the potential risks of the newly generated prion species to humans and animals.

Recent Publications:

Angers RC, Kang HE, Napier D, Browning S, Seward T, Mathiason C, Balachandran A, McKenzie D, Castilla J, Soto C, Jewell J, Graham C, Hoover EA, Telling GC.
Prion strain mutation determined by prion protein conformational compatibility and primary structure
Science. 2010 May 28;328(5982):1154-8.

Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C.
Molecular crosstalk between misfolded proteins in animal models of Alzheimer’s and prion diseases.
J Neurosci. 2010 Mar 31;30(13):4528-35.

Castilla J, Morales R, Saá P, Soto C.
Propagation of prion strains in vitro.
EMBO J. 27, 2557-2566; 2008.

Castilla J, Gonzaléz D, Saá P, Morales R, de Castro J, Soto C.
Crossing species barrier by in vitro replication of protein misfolding generates new infectious prions.
Cell. 134, 757-768; 2008.

Green KM, Castilla J, Seward TS, Napier DL, Jewell JE, Soto C, Telling GC.
Accelerated High Fidelity Prion Amplification Within and Across Prion Species Barriers.
PLOS Pathogens. 4, 1-12; 2008.

Saá P, Castilla J, Soto C.
Pre-symptomatic detection of prions in blood.
Science. 313, 92-4; 2006.

Soto C, Estrada L, Castilla J.
Amyloids, prions and the inherent infectious nature of misfolded protein aggregates.
Trends in Biochemical Sciences. 31, 150-155; 2006.

Castilla J, Saá P, Soto C.
Detection of prions in blood.
Nat. Med. 11, 982-985; 2005.

Castilla J, Saá P, Hetz C, Soto C.
In Vitro Generation of Infectious Scrapie Prions.
Cell. 121, 195-206; 2005.

Soto C, Castilla J.
The controversial protein-only hypothesis of prion propagation.
Nat Med. 10, S63-S67; 2004.

For more information:http://www.cicbiogune.es/secciones/investigacion/ficha_laboratorio.php?idioma=en&unidad=2&subgrupo=52

Email : vincent.beringue@jouy.inra.fr